USFDA Guidance: CMC Flexibilities to Accelerate Human Cellular and Gene Therapy Development

Human cellular and gene therapy (CGT) products are transforming modern medicine by offering innovative treatments for serious and life-threatening diseases such as cancer, genetic disorders, and chronic illnesses. However, the development and manufacturing of these therapies are often highly complex due to personalized production processes, advanced technologies, limited patient populations, and short product shelf-lives.

To support innovation while maintaining product quality and patient safety, the U.S. Food and Drug Administration (FDA) published the guidance titled “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application” in May 2026.

Purpose of the FDA Guidance

The guidance describes FDA’s current thinking on when CMC flexibilities may be appropriate during development and licensure of CGT products submitted under a Biologics License Application (BLA). According to the guidance, the FDA’s flexible approach is intended to:

• Expedite CGT development

• Support innovation

• Improve patient access

• Maintain rigorous quality standards

• Accommodate the unique characteristics of CGT products

Why Flexibility Is Needed for CGT Products

FDA acknowledges several unique challenges associated with cellular and gene therapy development, including:

• Complex manufacturing processes

• Limited manufacturing runs

• Small patient populations

• Advanced technologies

• Product characterization challenges

• Short product shelf-life

• Narrow production-to-administration timelines

These challenges make it difficult to apply conventional manufacturing and validation approaches used for traditional biologics. As a result, the FDA has identified regulatory flexibilities that can support CGT development while ensuring products remain:

• Safe

• Pure

• Potent

Flexible Approaches During Clinical Development

1. Phase-Appropriate CGMP Implementation

FDA explains that investigational CGT products used in Phase 1 clinical trials are generally exempt from full compliance with certain current Good Manufacturing Practice (CGMP) regulations under 21 CFR Part 211.

Instead, FDA encourages:

• Phase-appropriate manufacturing controls

• Process characterization studies

• Risk-based manufacturing oversight

2. Flexible Release Acceptance Criteria

FDA may allow relatively permissive release criteria for early-stage investigational CGT products provided patient safety is not compromised.

As development progresses:

• Product specifications should become more refined

• Acceptance criteria should become more defined

• Numerical release criteria should be established before Phase 2 or Phase 3 studies intended to demonstrate product effectiveness

This flexibility recognizes that early-stage manufacturing knowledge may still be evolving.

3. Risk-Based Comparability Approaches

Manufacturing changes are common during CGT development.

FDA recommends:

• Performing risk assessments for all manufacturing changes

• Evaluating the impact on product quality

• Using risk-based comparability studies

For minor, low-risk manufacturing changes, FDA may accept limited comparability data if product quality attributes remain acceptable.

4. Leveraging Prior Knowledge and Platform Technologies

As more CGT products are developed, FDA recognizes that sponsors may leverage prior experience and platform technologies across similar products.

This may include using shared:

• Analytical methods

• Stability data

• Validation strategies

• Comparability data

• Manufacturing knowledge

FDA may also allow the use of platform analytical procedures to reduce qualification and validation burdens during development.

5. Use of Voluntary Consensus Standards

FDA encourages sponsors to use recognized standards through the Standards Recognition Program for Regenerative Medicine Therapies.

Using recognized standards may:

• Improve regulatory predictability

• Reduce documentation burden

• Streamline submissions

Process Validation Flexibilities

1. Flexible Process Performance Qualification (PPQ)

Process Performance Qualification (PPQ) is essential for validating commercial manufacturing processes.

However, FDA acknowledges that CGT sponsors may face:

• Limited batch availability

• Small-scale manufacturing constraints

• Patient-specific production limitations

FDA does not require a fixed minimum number of PPQ batches.

Instead, sponsors are encouraged to justify the number of PPQ batches based on:

• Product understanding

• Process complexity

• Manufacturing controls

• Available experience

2. Releasing PPQ Batches for Clinical or Commercial Use

FDA may permit concurrent release of PPQ batches for:

• Clinical use

• Commercial distribution

provided the batches:

• Meet release specifications

• Remain within approved shelf-life requirements

This flexibility may help reduce manufacturing burden and accelerate patient access.

Commercial Specification Flexibilities

1. Flexible Product Release Strategies

Because CGT products may involve very small patient populations, only limited manufacturing lots may be available during BLA submission.

FDA may therefore allow flexible approaches when establishing:

• Commercial release specifications

• Acceptance criteria

particularly when statistically robust data are not yet feasible.

2. Flexible Analytical Method Validation

FDA does not specify a minimum number of lots required for analytical method validation.

In certain cases:

• A single representative lot may be acceptable

• Sponsors must still demonstrate scientific robustness and suitability of the method

3. Post-Approval Refinement of Specifications

FDA may allow sponsors to refine product release specifications after approval using additional commercial manufacturing data.

This approach supports the development of:

• More statistically robust acceptance criteria

• Improved long-term product understanding

Additional FDA Flexibilities

1. Flexible Stability Data Requirements

FDA generally recommends:

• Real-time stability data from three commercial lots

• At least six months of stability data

However, FDA may consider alternative approaches based on risk assessment.

Sponsors may also use:

• Stability data from representative clinical lots

• Data from similar products as supportive evidence

2. Exceptions for Reserve Samples

Under normal regulations, manufacturers must retain reserve samples from each product lot.

FDA recognizes that this may not be feasible for:

• Small-volume CGT products

• Patient-specific therapies

In such situations, FDA may consider exceptions to reserve sample retention requirements.

3. Alternative Analytical Methods

FDA also supports the use of alternative rapid analytical methods instead of traditional compendial methods where appropriate.

These methods may help:

• Reduce sample requirements

• Shorten testing timelines

• Enable faster product release

FDA may accept alternative methods if they demonstrate:

• Accuracy

• Sensitivity

• Specificity

• Reproducibility

• Proper validation

Conclusion

As cellular and gene therapies continue to evolve, this document provides important regulatory direction for sponsors preparing biologics license applications and developing next-generation treatments for serious and life-threatening diseases.

Reference

For complete details, refer to the official FDA guidance: Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application